The First Randomized Trial of THC + CBD for Brain Cancer: Encouraging Numbers, Tiny Sample

The Disease

Recurrent glioblastoma is among the most lethal diagnoses in medicine. Glioblastoma multiforme is the most aggressive primary brain tumor, accounting for roughly half of all malignant brain cancers. Standard first-line treatment — maximal surgical resection, radiotherapy, and temozolomide chemotherapy — extends median survival to about 15 months. When the cancer recurs — and it almost always does — options narrow dramatically. Median survival after recurrence is typically 6-9 months.

There is no standard second-line treatment that reliably extends life. Patients and their families know this. So do their oncologists.

Into this landscape, Twelves and colleagues introduced a question: could pharmaceutical-grade cannabinoids, added to standard chemotherapy, change the trajectory?

The Trial

The study was a Phase 1b trial — designed primarily for safety, with survival as a secondary measure. It had two parts.

Part 1 was open-label: six patients received nabiximols (Sativex) plus dose-intense temozolomide. The goal was to establish that the combination was tolerable and to find a workable dosing scheme.

Part 2 was what matters: a randomized, double-blind, placebo-controlled trial. Twelve patients received nabiximols; nine received placebo. Both groups took dose-intense temozolomide. Neither patients nor doctors knew who was getting the cannabinoid spray and who was getting an identical-looking placebo.

The Drug

Nabiximols (brand name Sativex) is a pharmaceutical-grade oromucosal spray manufactured by GW Pharmaceuticals (now Jazz Pharmaceuticals). Each spray delivers 2.7 mg of THC and 2.5 mg of CBD — roughly equal parts of each major cannabinoid, extracted from cannabis plants under pharmaceutical conditions. It is approved in multiple countries for MS spasticity but has never been approved for cancer.

Patients could take up to 12 sprays per day (32.4 mg THC + 30 mg CBD), with individualized dose escalation. The mean dose in the randomized portion was 7.5 sprays per day. The spray is applied inside the cheek or under the tongue — not smoked, not eaten, not vaped.

The Results

Safety

The primary finding: nabiximols plus temozolomide was safe and tolerable. The most common adverse events — vomiting, dizziness, fatigue, nausea, headache — were consistent with what you'd expect from both cannabinoids and chemotherapy. No new drug-drug interactions were identified. No unexpected toxicity emerged.

This mattered. Before this trial, the theoretical concern was that cannabinoids might interfere with chemotherapy metabolism or add intolerable central nervous system effects on top of a brain tumor. Neither happened.

Survival

The one-year survival difference was statistically significant (p = 0.042). In a larger trial, this p-value would be persuasive. In a trial of 21 patients, it's a signal — an important one, but not proof.

The Puzzle

One finding complicates the story. Progression-free survival at six months — the percentage of patients whose tumors hadn't grown — was 33% in both groups. Identical. The tumors progressed at the same rate regardless of whether patients received cannabinoids.

This raises an uncomfortable question: if cannabinoids didn't slow tumor growth, why did patients in the cannabinoid group live longer? Several hypotheses exist:

This ambiguity is why larger trials are essential. With 21 patients, you can't distinguish between these explanations.

The Researchers

Chris Twelves has spent his career in clinical cancer pharmacology — specifically, understanding how anticancer drugs behave in the body and how to use them more effectively. He held the Chair of Clinical Cancer Pharmacology and Oncology at the University of Leeds and was a consultant medical oncologist at St James's University Hospital. This was not a cannabis enthusiast testing a pet theory; it was a mainstream oncology pharmacologist evaluating a hypothesis generated by 20 years of preclinical research.

Susan Short, the trial's senior author, is Professor of Clinical Oncology and Neuro-Oncology at Leeds. The trial was funded by GW Pharmaceuticals, which provided the pharmaceutical-grade nabiximols — appropriate for a drug manufacturer testing its product, and declared as a conflict of interest in the publication.

What Comes Next

The ARISTOCRAT trial — "A Randomised phase II trial of temozolomide with or without cannabinoids in patients with recurrent glioblastoma" — is the direct consequence of Twelves' findings. Led by Susan Short at Leeds and coordinated by Cancer Research UK's Clinical Trials Unit at the University of Birmingham, it will randomize more than 230 patients at 14 NHS hospitals across England, Scotland, and Wales. Patients will receive temozolomide plus either nabiximols or placebo in a 2:1 ratio.

The primary outcome is overall survival. Secondary outcomes include PFS, quality of life, and adverse events. If the survival benefit seen in the Phase 1b trial replicates at this scale, ARISTOCRAT could provide the evidence needed to consider Phase III trials — and potentially the first approved cannabinoid anticancer therapy.

If it doesn't replicate — and the history of small encouraging oncology trials that fail at larger scale is long — it will establish that the Phase 1b survival difference was statistical noise rather than a biological signal. Either answer would be valuable.

The Honest Assessment

This study occupies an uncomfortable middle ground that is easy to misrepresent in either direction.

The optimistic misrepresentation: "Cannabis doubles brain cancer survival!" This extrapolates a 21-patient Phase 1b safety trial into a treatment recommendation. It ignores the identical PFS, the tiny sample, the lack of dose-response data, and the long history of small positive trials that fail at scale.

The dismissive misrepresentation: "It's only 21 patients, it means nothing." This ignores that the survival difference was statistically significant, that the safety data enabled a much larger trial, and that the preclinical mechanism supporting cannabinoid anticancer effects is reproduced across dozens of independent studies over 25 years.

The honest position: a pharmaceutical-grade THC+CBD combination can be safely added to standard chemotherapy for recurrent glioblastoma, and the first controlled survival data are encouraging. Whether the survival benefit is real will be determined by the ARISTOCRAT trial. Until then, nobody — not patients, not oncologists, not cannabis advocates — should treat this as proven.